Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India

Int J Tuberc Lung Dis. 2005 Aug;9(8):896-900.

Abstract

Setting: Tuberculosis Research Centre clinics at Chennai and Madurai, Tamil Nadu, South India.

Objectives: To investigate the prevalence and pattern of drug resistance among patients with HIV and pulmonary tuberculosis (PTB).

Design: Prospective cohort study of HIV-positive patients with PTB between January 2001 and May 2003. Sputum mycobacterial culture and drug susceptibility testing were performed.

Results: A total of 204 patients with positive sputum cultures for Mycobacterium tuberculosis were included; 167 of them were new cases, and 37 had a history of previous anti-tuberculosis treatment for > 1 month. Among the former, resistance to isoniazid (INH) was observed in 22 (13%) and MDR-TB in 7 (4.2%). Reported resistance rates in this geographic area among new cases ranged from 15% to 28% for INH and 2.8% to 3.4% for MDR (INH + rifampicin [RMP]). In contrast, among HIV-positive patients with a history of previous treatment, resistance was found to INH in 10 (27%) and to RMP in 7 (18.9%), while MDR-TB was seen in 5 (13.5%) patients.

Conclusion: Among new TB patients, MDR-TB is marginally higher in HIV-positive patients than in the non-HIV-infected population in this region. Standard treatment guidelines should be followed. Higher rates of drug resistance are observed among previously treated patients.

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Drug Resistance, Bacterial
  • Drug Resistance, Multiple*
  • HIV Infections / complications*
  • Humans
  • India / epidemiology
  • Prevalence
  • Prospective Studies
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / etiology

Substances

  • Antitubercular Agents